According to Auriga, United Therapeutics UTHR reported preliminary top-line results from the closely watched FREEDOM-M trial.
Auriga said that the primary endpoint was change in 6 Minute Walk Distance (6MWD) at 12 weeks for 228 patients that received 0.25 mg dose increments. “Results showed patients on oral Remodulin improved their median 6MWD by approximately 23 meters (p=0.0125). While the trial clearly met the pre-specified endpoints with a high degree of statistical significance, the magnitude of the 6MWT difference (23M) was not as large as we or the street was expecting (30 to 40M).”
United Therapeutics closed yesterday at $59.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in